Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsHans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Johannes Kowalewski, Claudia Berlin
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
A method of eliciting an immune response in an acute myeloid leukemia patient, comprising administering to the patient a population of activated T cells that kill the cancer cells, which present a peptide consisting of the amino acid sequence of AEQFRLEQI (SEQ ID NO:
A method of treating an acute myeloid leukemia patient, comprising administering to the patient a population of activated T cells that kill the cancer cells, which present a peptide consisting of the amino acid sequence of AEQFRLEQI (SEQ ID NO:
Dependencies are inferred from the claim text.